Antibody-Drug Conjugates (ADCs) are among the most promising precision therapies today. By combining the high targeting capability of monoclonal antibodies with the potent cytotoxicity of small-molecule drugs, they have become a new focal point in the R&D of cancer and immune diseases.
For pharmaceutical companies, ADCs signify an expansion of clinical pipelines; for Contract Development and Manufacturing Organizations (CDMOs), however, they represent both immense market opportunities and formidable manufacturing challenges. Since ADCs necessitate bridging the distinct technological realms of large molecules (biologics) and small molecules, CDMO executives must strike a delicate balance between “rapidly securing orders” and “ensuring professional service quality.” This dynamic intensifies the challenge of the Business Development (BD) role, underscoring its critical importance within the competitive landscape.
BD’s Core Pain Points: Bottlenecks in Speed and Knowledge Alignment
Pharmaceutical CDMO BD teams grapple daily with complex inquiries from global pharma clients, which may range from the feasibility of specific antibody-linker/payload combinations to knowledge benchmarking against existing pipelines. These requirements often span patents, academic literature, and internal know-how. However, fragmented knowledge resources make document organization and verification extremely time-consuming. BD members are forced to rely on repeated confirmations from R&D and regulatory experts, resulting in response cycles dragging on for weeks. This not only decelerates the speed of order intake and project initiation but also erodes client confidence in the CDMO’s professionalism and collaborative efficiency.
A Typical Scenario :
When a pharmaceutical client submits a requirements document containing multi-faceted inquiries, BD must invest significant time curating knowledge. Striving for comprehensiveness often requires additional manpower or even the direct involvement of senior executives. The tedious back-and-forth of documentation severely delays proposal progress and degrades the client cooperation experience.
[Founder’s View] Specialized Models Are the Future Solution for CDMOs
He believe that in the ADC domain, the development of AI models does not necessarily hinge on general-purpose Large Language Models (LLMs). For CDMOs, specialized Small Language Models (SLMs) represent the true solution that balances efficiency, security, and practical deployability:
- Resource Efficiency : General-purpose LLMs require massive, high-cost GPU and power resources, making them difficult to operate practically within a CDMO environment. Specialized small models, optimized for specific domains, offer higher computational efficiency and lower deployment costs.
- Knowledge Security and Internal Sharing: ADC language models focus on CDMO requirements, R&D processes, and clinical trial knowledge. They can be deployed internally within the CDMO to ensure knowledge does not leak. At the same time, they promote professional inquiry and feedback exchanges among R&D personnel, facilitating the healthy accumulation of knowledge within the organization.
- Multi-layered Application: Through a “Research/Exploration/Exploitation” layered model design, CDMOs can not only accelerate process R&D and environmental parameter inference but also realize the value of AI in generating requirement alignment documents and providing strategic support.
Specialized models liberate BD from the bottleneck of information organization, transforming them into AI-driven knowledge mediators. Future BD professionals will not merely be windows for taking orders but will become key engines driving breakthrough and innovation in the ADC industry, creating higher value for pharmaceutical CDMOs and drug developers.
Solution: An Intelligent Curator of Existing Knowledge
The ADC-specific language model and AI agent launched by therapiAI bring a brand-new mindset to BD. It does not merely provide answers but constructs support scenarios across three levels: Research, Exploration, and Exploitation:
When clients submit multiple requirements, the ADC model can rapidly cross-reference these requests and instantly generate knowledge summaries with source citations. BD members no longer need to repeatedly search through documents. By integrating literature, patents, and internal data, the team can focus on collaboration priorities faster and dedicate their energy to discussing “strategic topics” with clients.
After introducing the ADC-specific language model, BD teams can quickly generate structured knowledge summaries with reliable sources, making responses more timely, professional, and persuasive. Senior executives can concentrate their energy on core decisions. Ultimately, the efficiency of requirement alignment is significantly improved, proposal and project initiation speeds are accelerated, and client satisfaction is simultaneously enhanced.
Michael Han
As the founder of therapiAI, Michael has always focused on the forefront of pharmaceutical technology. Through this column, he will periodically share global ADC market dynamics, CDMO digital transformation trends, and deep insights into AI in the biotech field. We invite you to stay tuned to master first-hand industry perspectives and practical implementation strategies, joining us in envisioning the future of medical innovatio
